CST, 96780S, TFPI2 (F8I2H) Rabbit Monoclonal Antibody

Monoclonal Antibody for studying TFPI2. Validated for Western Blotting. Available in 2 sizes. Highly specific and rigorously validated in-house, TFPI2 (F8I2H) Rabbit Monoclonal Antibody (CST #96780) is ready to ship. Product Usage Information Western Blotting: 1:1000 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting Specificity / Sensitivity TFPI2 (F8I2H) Rabbit Monoclonal Antibody recognizes endogenous levels of total TFPI2 protein. Species Reactivity: Human Source / Purification Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ile135 of human TFPI2 protein. Background Metastasis is a multi-step process that generally leads to reduced cell adhesion and extracellular matrix (ECM) degradation. Most metastatic cancer cells secrete matrix metalloproteinases (MMPs), which lead to ECM hydrolysis and tumor invasion (1-3). Tissue factor pathway inhibitor 2 (TFPI2) is a serine protease inhibitor involved in various pathways that modulate tumor growth and metastasis. TFPI2 was initially discovered in a screen for protease inhibitors using skin fibroblasts (1) and is in the Kunitz-type serine protease inhibitor family. TFPI2 is produced and secreted into the ECM by endothelial cells, smooth muscle cells, fibroblasts, keratinocytes, and urothelium (1-3). TFPI2 was shown to strongly prevent ECM hydrolysis by inhibiting plasminogen and MMPs, underscoring its importance in cancer metastases (1-3). There is increased research interest in studying TFPI2 function as a tumor suppressor and its role in regulatory pathways involving angiogenesis, ECM degradation, and gene expression. TFPI2 levels are significantly reduced in many invasive tumors, such as glioma (4), prostate cancer, melanoma, pancreatic ductal adenocarcinoma (5), breast (6,7), and kidney cancer (8). The methylation state of the gene promoter has been linked to tumor malignancy (10). Increased TFPI2 expression in cancer cells has been shown to inhibit tumor growth and metastasis by modulating ECM remodeling and angiogenesis (10). Given the roles TFPI2 plays in cancer biology, the protein is a promising biomarker and drug target for cancer therapies (8,9). Alternate Names FLJ21164; P48307; Placental protein 5; PP5; REF1; retinal pigment epithelium cell factor 1; TFPI-2; TFPI2; Tissue factor pathway inhibitor 2 Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 15-35 Source/Isotype: Rabbit IgG